333 related articles for article (PubMed ID: 16146544)
1. Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia.
Tsironi M; Polonifi K; Deftereos S; Farmakis D; Andriopoulos P; Moyssakis I; Aessopos A
Eur J Haematol; 2005 Oct; 75(4):355-8. PubMed ID: 16146544
[TBL] [Abstract][Full Text] [Related]
2. Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone.
Tavecchia L; Masera N; Russo P; Cirò A; Vincenzi A; Vimercati C; Masera G
Haematologica; 2006 Jun; 91(6 Suppl):ECR19. PubMed ID: 16785138
[TBL] [Abstract][Full Text] [Related]
3. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report.
Tsironi M; Deftereos S; Andriopoulos P; Farmakis D; Meletis J; Aessopos A
Eur J Haematol; 2005 Jan; 74(1):84-5. PubMed ID: 15613114
[TBL] [Abstract][Full Text] [Related]
4. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
Marsella M; Borgna-Pignatti C
Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
[TBL] [Abstract][Full Text] [Related]
5. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
Kolnagou A; Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649
[TBL] [Abstract][Full Text] [Related]
6. Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.
Huang YC; Chang JS; Wu KH; Peng CT
Hemoglobin; 2006; 30(2):229-38. PubMed ID: 16798648
[TBL] [Abstract][Full Text] [Related]
7. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
[TBL] [Abstract][Full Text] [Related]
8. Recent developments in iron chelation therapy.
Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
[TBL] [Abstract][Full Text] [Related]
9. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
[No Abstract] [Full Text] [Related]
10. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
[TBL] [Abstract][Full Text] [Related]
11. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
[TBL] [Abstract][Full Text] [Related]
12. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
13. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
[TBL] [Abstract][Full Text] [Related]
14. Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report.
Porcu M; Landis N; Salis S; Corda M; Orrù P; Serra E; Usai B; Matta G; Galanello R
Eur J Heart Fail; 2007 Mar; 9(3):320-2. PubMed ID: 17029959
[TBL] [Abstract][Full Text] [Related]
15. Combined iron chelation therapy.
Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
[TBL] [Abstract][Full Text] [Related]
16. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
Wu KH; Chang JS; Tsai CH; Peng CT
Ann Hematol; 2004 Jul; 83(7):471-3. PubMed ID: 14658011
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
Vichinsky E; Pakbaz Z; Onyekwere O; Porter J; Swerdlow P; Coates T; Lane P; Files B; Mueller BU; Coïc L; Forni GL; Fischer R; Marks P; Rofail D; Abetz L; Baladi JF
Acta Haematol; 2008; 119(3):133-41. PubMed ID: 18408362
[TBL] [Abstract][Full Text] [Related]
18. Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.
Hatzipantelis ES; Karasmanis K; Perifanis V; Vlachaki E; Tziomalos K; Economou M
Hemoglobin; 2014; 38(2):111-4. PubMed ID: 24351163
[TBL] [Abstract][Full Text] [Related]
19. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
Wu SF; Peng CT; Wu KH; Tsai CH
Hemoglobin; 2006; 30(2):215-8. PubMed ID: 16798646
[TBL] [Abstract][Full Text] [Related]
20. Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial.
Calvaruso G; Vitrano A; Di Maggio R; Ballas S; Steinberg MH; Rigano P; Sacco M; Telfer P; Renda D; Barone R; Maggio A;
Blood Cells Mol Dis; 2014 Dec; 53(4):265-71. PubMed ID: 24814618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
